Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada

被引：5
|
作者：
Deceuninck, Genevieve [1 ,2 ]
Brousseau, Nicholas [1 ,2 ]
Lefebvre, Brigitte [3 ]
Quach, Caroline [4 ,5 ]
Tapiero, Bruce [6 ]
Bui, Yen-Giang [2 ]
Desjardins, Michael [4 ,7 ]
De Wals, Philippe [1 ,2 ,8 ,9 ]
机构：
[1] CHU Quebec, Equipe Rech Vaccinat, Ctr Rech, Quebec City, PQ, Canada
[2] Inst Natl Sante Publ Quebec, Direct Risques Biol, Quebec City, PQ, Canada
[3] Inst Natl Sante Publ Quebec, Lab Sante Epubl Quebec, Ste Anne De Bellevue, PQ, Canada
[4] Univ Montreal, Dept Microbiol Infect Dis & Immunol, Montreal, PQ, Canada
[5] CHU St Justine, Clin Dept Lab Med, Div Med Microbiol, Montreal, PQ, Canada
[6] CHU St Justine, Serv Malad Infect, Montreal, PQ, Canada
[7] CHU Montreal, Div Infect Dis, Montreal, PQ, Canada
[8] Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ, Canada
[9] Ctr Rech Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
来源：
VACCINE | 2023年 / 41卷 / 38期
关键词：
Vaccine effectiveness; Pneumococcal conjugated vaccine; Serotype-3; Children; Invasive pneumococcal disease; IMMUNOGENICITY; SAFETY;
D O I：
10.1016/j.vaccine.2023.07.049
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7 was replaced by PCV10 in 2009, by PCV13 in 2011 and by PCV10 in 2018, without catch-up in all instances. The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (& GE;1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness with the number of doses. PCV13 protection against serotype 3 IPD seems to be short-lived.
引用
收藏
页码：5486 / 5489
页数：4
相关论文
共 50 条
  • [1] Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada
    Ricketson, Leah J.
    Conradi, Nicholas G.
    Vanderkooi, Otto G.
    Kellner, James D.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (01) : 22 - 27
  • [2] Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada
    De Wals, Philippe
    Deceuninck, Genevieve
    De Serres, Gaston
    [J]. VACCINE, 2016, 34 (18) : 2053 - 2054
  • [3] Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada
    Deceuninck, Genevieve
    De Serres, Gaston
    Boulianne, Nicole
    Lefebvre, Brigitte
    De Wals, Philippe
    [J]. VACCINE, 2015, 33 (23) : 2684 - 2689
  • [4] Complications of Pneumococcal Bacteremia After Thirteen-valent Conjugate Vaccine Withdrawal
    Tagarro, Alfredo
    Bote, Patricia
    Sanchez, Aida
    Otheo, Enrique
    Sanz, Juan-Carlos
    Sanz-Rosa, David
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (12) : 1281 - 1287
  • [5] Effectiveness of three pneumococcal conjugate vaccines (PCV) to prevent invasive pneumococcal disease in Quebec, Canada
    Cane, Alejandro
    Hamelin, Bettina
    Isturiz, Raul
    [J]. VACCINE, 2016, 34 (18) : 2051 - 2052
  • [6] Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine
    Susanna Esposito
    Leonardo Terranova
    Maria Francesca Patria
    Gian Luigi Marseglia
    Michele Miraglia del Giudice
    Alessandro Bodini
    Alberto Martelli
    Eugenio Baraldi
    Oscar Mazzina
    Claudia Tagliabue
    Amelia Licari
    Valentina Ierardi
    Mara Lelii
    Nicola Principi
    [J]. BMC Infectious Diseases, 16
  • [7] Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine
    Esposito, Susanna
    Terranova, Leonardo
    Patria, Maria Francesca
    Marseglia, Gian Luigi
    del Giudice, Michele Miraglia
    Bodini, Alessandro
    Martelli, Alberto
    Baraldi, Eugenio
    Mazzina, Oscar
    Tagliabue, Claudia
    Licari, Amelia
    Ierardi, Valentina
    Lelii, Mara
    Principi, Nicola
    [J]. BMC INFECTIOUS DISEASES, 2016, 16
  • [8] Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
    Nikolova, Kristiana Alexandrova
    Andersson, Mikael
    Slotved, Hans-Christian
    Koch, Anders
    [J]. VACCINES, 2021, 9 (10)
  • [9] Hyporesponsiveness to the infecting serotype after vaccination of children with seven-valent pneumococcal conjugate vaccine following invasive pneumococcal disease
    Tamura, Kazuyo
    Matsubara, Kousaku
    Ishiwada, Naruhiko
    Nishi, Junichiro
    Ohnishi, Hidenori
    Suga, Shigeru
    Ihara, Toshiaki
    Chang, Bin
    Akeda, Yukihiro
    Oishi, Kazunori
    [J]. VACCINE, 2014, 32 (13) : 1444 - 1450
  • [10] The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease
    Gaviria-Agudelo, Claudia L.
    Jordan-Villegas, Alejandro
    Garcia, Carla
    McCracken, George H., Jr.
    [J]. JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2017, 6 (03) : 253 - 259
12345